Darexaban: all 25 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male SubjectsCompletedNCT01657981Phase 1
- A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the BodyCompletedNCT01655056Phase 1
- A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly SubjectsCompletedNCT01514825Phase 1
- A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy SubjectsCompletedNCT01514812Phase 1
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their EffectsCompletedNCT01424332Phase 1
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their EffectsCompletedNCT01409616Phase 1
- To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their EffectsCompletedNCT01409603Phase 1
- To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)CompletedNCT01406002Phase 1
- To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)CompletedNCT01405989Phase 1
- A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 TabletCompletedNCT01125670Phase 1
- A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-BCompletedNCT01125657Phase 1
- A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150CompletedNCT01118559Phase 1
- YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical IllnessCompletedNCT01028950Phase 3
- Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary SyndromesCompletedNCT00994292Phase 2
- A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal SurgeryCompletedNCT00942435Phase 3
- A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial FibrillationCompletedNCT00938730Phase 2
- Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower ExtremitiesCompletedNCT00937911Phase 3
- Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous ThromboembolismCompletedNCT00937820Phase 3
- Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement SurgeryCompletedNCT00917254Phase 2/3
- Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement SurgeryCompletedNCT00913120Phase 2/3
- A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement SurgeryCompletedNCT00902928Phase 2/3
- A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement SurgeryCompletedNCT00595426Phase 2
- Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial FibrillationCompletedNCT00448214Phase 2
- Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee ReplacementCompletedNCT00408239Phase 2
- Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)CompletedNCT00353678Phase 2